Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDC-G305 in advanced cancer
NCT02015416Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2013
- Primary completion
- Dec 2016
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NY-ESO-1 protein + GLA-SE in melanoma, ovarian cancer, sarcoma and 2 more, sponsored by Merck & Co. Primary endpoint: Safety and tolerability at 1 year. Started Nov 2013; status: completed.
02
Drugs
NY-ESO-1 protein + GLA-SE
03
Conditions
melanomaovarian cancersarcomanon-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT02015416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015416.